Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions

Abstract Breast cancer resistance protein (BCRP), a member of the ATP-binding cassette transporter family, plays a key role in the efflux of various drugs and is linked to multidrug resistance in cancer therapy. Flavonoids, particularly those with a flavonol backbone, have shown promise as inhibitor...

Full description

Saved in:
Bibliographic Details
Main Authors: Kyeong-Ryoon Lee, Min-Ji Kang, Min Ju Kim, Yiseul Im, Hyeon-Cheol Jeong, Yoon-Jee Chae
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-13908-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849766932385890304
author Kyeong-Ryoon Lee
Min-Ji Kang
Min Ju Kim
Yiseul Im
Hyeon-Cheol Jeong
Yoon-Jee Chae
author_facet Kyeong-Ryoon Lee
Min-Ji Kang
Min Ju Kim
Yiseul Im
Hyeon-Cheol Jeong
Yoon-Jee Chae
author_sort Kyeong-Ryoon Lee
collection DOAJ
description Abstract Breast cancer resistance protein (BCRP), a member of the ATP-binding cassette transporter family, plays a key role in the efflux of various drugs and is linked to multidrug resistance in cancer therapy. Flavonoids, particularly those with a flavonol backbone, have shown promise as inhibitors of BCRP activity; however, their specific inhibitory effects are not fully understood. This study explored the inhibitory effects of 77 flavonols on BCRP and identified 22 compounds with significant inhibitory activity. Among them, 14 flavonols had half-maximal inhibitory concentrations (IC50) values below 5 µM, effectively reversing BCRP-mediated resistance to SN-38 in vitro. Molecular docking analysis revealed key interactions between flavonols and BCRP, including π-stacking, hydrogen bonding, and hydrophobic interactions. Structural modifications, including hydroxylation and methylation, enhanced the binding affinity of the flavonols. In vivo studies with 3,4′-dimethoxyflavone and 3,6,3′,4′-tetramethoxyflavone resulted in increased systemic exposure to sulfasalazine, a known BCRP substrate. These findings provide mechanistic insights into flavonol-BCRP interactions, suggesting their potential to enhance drug exposure and efficacy. Future research should focus on clinical applications to explore the therapeutic potential of these flavonols for improved drug responses.
format Article
id doaj-art-109d6fe204fb48ab85c2f9331b81a0de
institution DOAJ
issn 2045-2322
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-109d6fe204fb48ab85c2f9331b81a0de2025-08-20T03:04:25ZengNature PortfolioScientific Reports2045-23222025-08-0115111310.1038/s41598-025-13908-1Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactionsKyeong-Ryoon Lee0Min-Ji Kang1Min Ju Kim2Yiseul Im3Hyeon-Cheol Jeong4Yoon-Jee Chae5Laboratory Animal Resource Center, Korea Research Institute of Bioscience and BiotechnologyCollege of Pharmacy, Woosuk UniversityLaboratory Animal Resource Center, Korea Research Institute of Bioscience and BiotechnologyLaboratory Animal Resource Center, Korea Research Institute of Bioscience and BiotechnologyLaboratory Animal Resource Center, Korea Research Institute of Bioscience and BiotechnologyCollege of Pharmacy, Woosuk UniversityAbstract Breast cancer resistance protein (BCRP), a member of the ATP-binding cassette transporter family, plays a key role in the efflux of various drugs and is linked to multidrug resistance in cancer therapy. Flavonoids, particularly those with a flavonol backbone, have shown promise as inhibitors of BCRP activity; however, their specific inhibitory effects are not fully understood. This study explored the inhibitory effects of 77 flavonols on BCRP and identified 22 compounds with significant inhibitory activity. Among them, 14 flavonols had half-maximal inhibitory concentrations (IC50) values below 5 µM, effectively reversing BCRP-mediated resistance to SN-38 in vitro. Molecular docking analysis revealed key interactions between flavonols and BCRP, including π-stacking, hydrogen bonding, and hydrophobic interactions. Structural modifications, including hydroxylation and methylation, enhanced the binding affinity of the flavonols. In vivo studies with 3,4′-dimethoxyflavone and 3,6,3′,4′-tetramethoxyflavone resulted in increased systemic exposure to sulfasalazine, a known BCRP substrate. These findings provide mechanistic insights into flavonol-BCRP interactions, suggesting their potential to enhance drug exposure and efficacy. Future research should focus on clinical applications to explore the therapeutic potential of these flavonols for improved drug responses.https://doi.org/10.1038/s41598-025-13908-1Breast cancer resistance proteinFlavonolsDrug interactionsDrug resistanceSN-38
spellingShingle Kyeong-Ryoon Lee
Min-Ji Kang
Min Ju Kim
Yiseul Im
Hyeon-Cheol Jeong
Yoon-Jee Chae
Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions
Scientific Reports
Breast cancer resistance protein
Flavonols
Drug interactions
Drug resistance
SN-38
title Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions
title_full Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions
title_fullStr Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions
title_full_unstemmed Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions
title_short Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions
title_sort inhibition of breast cancer resistance protein by flavonols in vitro in vivo and in silico implications of the interactions
topic Breast cancer resistance protein
Flavonols
Drug interactions
Drug resistance
SN-38
url https://doi.org/10.1038/s41598-025-13908-1
work_keys_str_mv AT kyeongryoonlee inhibitionofbreastcancerresistanceproteinbyflavonolsinvitroinvivoandinsilicoimplicationsoftheinteractions
AT minjikang inhibitionofbreastcancerresistanceproteinbyflavonolsinvitroinvivoandinsilicoimplicationsoftheinteractions
AT minjukim inhibitionofbreastcancerresistanceproteinbyflavonolsinvitroinvivoandinsilicoimplicationsoftheinteractions
AT yiseulim inhibitionofbreastcancerresistanceproteinbyflavonolsinvitroinvivoandinsilicoimplicationsoftheinteractions
AT hyeoncheoljeong inhibitionofbreastcancerresistanceproteinbyflavonolsinvitroinvivoandinsilicoimplicationsoftheinteractions
AT yoonjeechae inhibitionofbreastcancerresistanceproteinbyflavonolsinvitroinvivoandinsilicoimplicationsoftheinteractions